ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - sitagliptin as monohydrate phosphate - טבליות מצופות פילם - sitagliptin as monohydrate phosphate 25 mg - sitagliptin - sitagliptin - januvia is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus.important limitations of use:januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings.januvia has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januvia.

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - sitagliptin as monohydrate phosphate - טבליות מצופות פילם - sitagliptin as monohydrate phosphate 50 mg - sitagliptin - sitagliptin - januvia is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus.important limitations of use:januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings.januvia has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januvia.

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - sitagliptin as monohydrate phosphate - טבליות מצופות פילם - sitagliptin as monohydrate phosphate 100 mg - sitagliptin - sitagliptin - januvia is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus.important limitations of use:januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings.januvia has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januvia.

ישראל - עברית - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

ישראל - עברית - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

ישראל - עברית - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

ישראל - עברית - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

ישראל - עברית - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 15 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

ישראל - עברית - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 15 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

ישראל - עברית - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 25 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.